Zugmaier, Gerhard and Goekbuget, Nicola and Klinger, Matthias and Viardot, Andreas and Stelljes, Matthias and Neumann, Svenja and Horst, Heinz-A. and Marks, Reinhard and Faul, Christoph and Diedrich, Helmut and Reichle, Albrecht and Brueggemann, Monika and Holland, Chris and Schmidt, Margit and Einsele, Hermann and Bargou, Ralf C. and Topp, Max S. (2015) Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. BLOOD, 126 (24). pp. 2578-2584. ISSN 0006-4971, 1528-0020
Full text not available from this repository. (Request a copy)Abstract
This long-term follow-up analysis evaluated overall survival (OS) and relapse-free survival (RFS) in a phase 2 study of the bispecific T-cell engager antibody construct blinatumomab in 36 adults with relapsed/refractoryB-precursor acute lymphoblastic leukemia (ALL). In the primary analysis, 25 (69%) patients with relapsed/refractory ALL achieved complete remission with full (CR) or partial (CRh) hematologic recovery of peripheral blood counts within the first 2 cycles. Twenty-five patients (69%) had a minimal residual disease(MRD) response (<10(-4) blasts), including 22 CR/CRh responders, 2 patients with hypocellular bone marrow, and 1 patient with normocellular bone marrow but low peripheral counts. Ten of the 36 patients (28%) were long-term survivors (OS >= 30 months). Median OS was 13.0 months (median follow-up, 32.6 months). MRD response was associated with significantly longer OS (Mantel-Byar P = .009). All 10 long-term survivors had an MRD response. Median RFS was 8.8 months (median follow-up, 28.9 months). A plateau for RFS was reached after similar to 18 months. Six of the 10 long-term survivors remained relapse-free, including 4 who received allogeneic stem cell transplantation (allo-SCT) as consolidation for blinatumomab and 2 who received 3 additional cycles of blinatumomab instead of allo-SCT. Three long-term survivors had neurologic events or cytokine release syndrome, resulting in temporary blinatumomab discontinuation; all restarted blinatumomab successfully. Long-term survivors had more pronounced T-cell expansion than patients with OS <30 months.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; ANTIBODY BLINATUMOMAB; ENGAGING ANTIBODY; ADULT PATIENTS; RELAPSE; CHEMOTHERAPY; THERAPY; SALVAGE; CANCER; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 29 Apr 2019 08:25 |
| Last Modified: | 29 Apr 2019 08:25 |
| URI: | https://pred.uni-regensburg.de/id/eprint/4290 |
Actions (login required)
 |
View Item |
